INTRODUCTION: Focal adhesion kinase (FAK) plays a significant role in cancer cell survival signaling and is overexpressed in various malignancies, including lung cancer. Previous studies suggest that FAK overexpression is an independent factor predicting poor prognosis in non-small-cell lung cancer (NSCLC). The aim of this study is to confirm these findings specifically in stage I NSCLC. METHODS: A retrospective tissue microarray (TMA) analysis of FAK protein expression by immunohistochemistry was performed in 157 surgically resected stage I NSCLC specimen and in the corresponding matched normal lung tissue. The FAK 4.47 monoclonal antibody was used for FAK immunostaining. The scoring system of triplicate tumor cores included intensity of staining plus extent of staining for a composite score that ranged from 0 to 6. The association between FAK score and survival was evaluated. RESULTS: There were 103 stage IA and 54 stage IB patients, with mean follow-up of 5.5 years. Normal lung alveoli and interstitial tissue had mean FAK score of 0 (median score 0, range 0 to 2). Tumor samples had mean FAK score 3.1 (median score 3.5, range 0-6), with 57% of the samples having FAK score ≥ 3. Continuous FAK score was not associated with demographic data, tumor histology, or grade, nor survival in this cohort of stage I NSCLC patients. CONCLUSIONS: FAK is expressed in more than 50% of stage I NSCLC lung cancer but not in normal lung alveoli and interstitial tissue. FAK expression is not associated with survival outcome in this North American cohort.
INTRODUCTION:Focal adhesion kinase (FAK) plays a significant role in cancer cell survival signaling and is overexpressed in various malignancies, including lung cancer. Previous studies suggest that FAK overexpression is an independent factor predicting poor prognosis in non-small-cell lung cancer (NSCLC). The aim of this study is to confirm these findings specifically in stage I NSCLC. METHODS: A retrospective tissue microarray (TMA) analysis of FAK protein expression by immunohistochemistry was performed in 157 surgically resected stage I NSCLC specimen and in the corresponding matched normal lung tissue. The FAK 4.47 monoclonal antibody was used for FAK immunostaining. The scoring system of triplicate tumor cores included intensity of staining plus extent of staining for a composite score that ranged from 0 to 6. The association between FAK score and survival was evaluated. RESULTS: There were 103 stage IA and 54 stage IB patients, with mean follow-up of 5.5 years. Normal lung alveoli and interstitial tissue had mean FAK score of 0 (median score 0, range 0 to 2). Tumor samples had mean FAK score 3.1 (median score 3.5, range 0-6), with 57% of the samples having FAK score ≥ 3. Continuous FAK score was not associated with demographic data, tumor histology, or grade, nor survival in this cohort of stage I NSCLCpatients. CONCLUSIONS:FAK is expressed in more than 50% of stage I NSCLC lung cancer but not in normal lung alveoli and interstitial tissue. FAK expression is not associated with survival outcome in this North American cohort.
Authors: Julian Carretero; Takeshi Shimamura; Klarisa Rikova; Autumn L Jackson; Matthew D Wilkerson; Christa L Borgman; Matthew S Buttarazzi; Benjamin A Sanofsky; Kate L McNamara; Kathleyn A Brandstetter; Zandra E Walton; Ting-Lei Gu; Jeffrey C Silva; Katherine Crosby; Geoffrey I Shapiro; Sauveur-Michel Maira; Hongbin Ji; Diego H Castrillon; Carla F Kim; Carlos García-Echeverría; Nabeel Bardeesy; Norman E Sharpless; Neil D Hayes; William Y Kim; Jeffrey A Engelman; Kwok-Kin Wong Journal: Cancer Cell Date: 2010-06-15 Impact factor: 31.743
Authors: M D Schaller; C A Borgman; B S Cobb; R R Vines; A B Reynolds; J T Parsons Journal: Proc Natl Acad Sci U S A Date: 1992-06-01 Impact factor: 11.205
Authors: Harry M Lightfoot; Amy Lark; Chad A Livasy; Dominic T Moore; David Cowan; Lynn Dressler; Rolf J Craven; William G Cance Journal: Breast Cancer Res Treat Date: 2004-11 Impact factor: 4.872
Authors: Vita M Golubovskaya; Richard Finch; Frederick Kweh; Nicole A Massoll; Martha Campbell-Thompson; Margaret R Wallace; William G Cance Journal: Mol Carcinog Date: 2008-05 Impact factor: 4.784
Authors: Hee Boong Park; Vita Golubovskaya; Lihui Xu; Xihui Yang; Jin Woo Lee; Sean Scully; Rolf Joseph Craven; William G Cance Journal: Biochem J Date: 2004-03-01 Impact factor: 3.857
Authors: Ying Zhou; Jason Dang; Kung-Yen Chang; Edwin Yau; Pedro Aza-Blanc; Jorge Moscat; Tariq M Rana Journal: Cancer Res Date: 2016-10-01 Impact factor: 12.701